4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1494 ongoing clinical trials involving Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Of the 1494 trials,404 trials are in Phase II
Furthermore, 371 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Acute Lymphocytic Leukemia, an oncology indication. The highest number of ongoing clinical trials involving Acute Lymphocytic Leukemia is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions involved in Acute Lymphocytic Leukemia-related drug trials.

University of Texas MD Anderson Cancer Center: The leading ongoing Acute Lymphocytic Leukemia related clinical trial sponsor

University of Texas MD Anderson Cancer Center, a leading cancer care center in the US, is the top sponsor for Acute Lymphocytic Leukemia-related ongoing clinical trials.

National Cancer Institute US, Beijing Boren Hospital, Fred Hutchinson Cancer Research Center, and Fred Hutchinson/University of Washington Cancer Consortium are a few other notable sponsors for clinical trials involving Acute Lymphocytic Leukemia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Acute Lymphocytic Leukemia

Dasatinib (Sprycel), Imatinib mesylate (Gleevec/ Zuciel/ QTI571/ Glivec/ Glivec GIST, Tisagenlecleucel (Kymriah), and Blinatumomab (Blincyto) are among the key marketed drugs involving Acute Lymphocytic Leukemia.     

Dasatinib (Sprycel) is an anti-neoplastic agent. It functions via Bcr-Abl Tyrosine Kinase (EC 2.7.10.2) Inhibitor mechanism of action. It is formulated as tablets, film coated tablets, coated tablets and powder for suspension for oral administration. It is marketed for the treatment of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), and Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). Dasatinib was first approved in 2006 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Bristol-Myers Squibb Co, and Otsuka America Pharmaceutical Inc.

Imatinib mesylate (Gleevec/ Zuciel/ QTI571/ Glivec/ Glivec GIST) is an anti-neoplastic agent. It functions via Bcr-Abl Tyrosine Kinase (EC 2.7.10.2) Inhibitor mechanism of action. It is formulated as hard gelatin capsules, tablets, coated tablets and film coated tablets for oral route of administration. It is marketed for the treatment of Acute Lymphocytic Leukemia and several other indications including Dermatofibrosarcoma Protuberans (DFSP), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Myelodysplastic Syndrome, Gastrointestinal Stromal Tumor (GIST), Myeloproliferative Disorders, Acute Lymphoblastic Lymphoma, Hypereosinophilic Syndrome, Pediatric Cancer, Systemic Mastocytosis. It was first approved in 2001 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Novartis AG and its subsidiaries.